Navigation Links
Rheumatoid Arthritis Patient Share of Actemra Projected to Exceed Patient Share of Cimzia and Simponi Among the Medicare Population
Date:11/3/2010

EXTON, Pa., Nov. 3, 2010 /PRNewswire/ -- Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010.  This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.

Despite the availability of newer TNF-alpha inhibitors, the TNF refractory market still remains relatively large. As many as one-fourth of first-time biologic users ultimately require a switch to another biologic agent due to poor response or waning efficacy of TNF-alpha inhibitors. However, the newer TNF-alpha inhibitors and biologic agents with alternative mechanisms of action are still perceived as less efficacious and less safe compared to the established TNF-alpha inhibitors.

The patient market share for the newest biologic agent, Genentech-Roche's Actemra (launched in January 2010), is currently estimated to be less than 5 percent among biologic-treated, rheumatoid arthritis (RA) patients.  However, according to surveyed rheumatologists' projections, the patient share of Actemra among the Medicare RA population is projected to exceed the patient share estimates of UCB's Cimzia and Centocor Ortho Biotech's Simponi in the next six months.  Furthermore, the patient share of Actemra among rheumatologists with in-office-infusion capability is projected to increase by more than 50 percent in the next six months.  

Amgen/Pfizer's Enbrel and Abbott Labs' Humira are currently the preferred first- and second-line biologic agents, respectively, among surveyed rheumatologists for the treatment of RA. However, almost one-fifth of rheumatologists cited decreased usage of both Enbrel an
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists Expect Well-Established TNF-Alpha Inhibitors to Lose Considerable Patient Share to Newer Agents in This Drug Class
2. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
3. Deadline Approaching for UCB Rheumatoid Arthritis Family Scholarship
4. CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
5. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
8. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
9. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
10. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
11. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to benefit ... and Green Valley Country Club in Lafayette Hill, PA. Over the past 26 years, ... million for programs and services designed to support patients and their families during their ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... law firms and government entities, announced today that it has hired Scott Sanderson, ... Consultant. In this capacity, Sanderson will be responsible for establishing and managing ...
(Date:9/1/2015)... ... 01, 2015 , ... Zecurion, a leading developer of data loss prevention solutions, ... endpoint DLP developed specifically for Mac OS. , In June 2015, the company successfully ... information security professionals had participated. The beta test done by the developer community enabled ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Two of ... cross cultural relations through food and dining. , Recently named “the next big ... Luigi Diotaiuti are known for telling the whole story behind food and reclaiming culinary ...
(Date:9/1/2015)... ... September 01, 2015 , ... METTLER ... Instruments in accordance with GMP requirements“ , featuring Ed Szczesny (Quality Assurance, Rhodes ... at 11:00 EDT (15:00 GMT). , Calibration, qualification, and the appropriate level ...
Breaking Medicine News(10 mins):Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:Zecurion Announces Endpoint Security for Mac 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2
... National Institute of Biomedical Imaging and Bioengineering (NIBIB) Laboratory ... technique that allows researchers to visualize fine details of ... insight into how cells are organized and how they ... online this week in Nature Methods . ...
... type 2 diabetes are not consuming sufficiently healthy diets and ... a new study by researchers at Wake Forest University School ... the August issue of the Journal of the American ... diabetes, especially type 2 diabetes, is being able to manage ...
... , , ATLANTA, ... GTIV ), a leading provider of comprehensive home health services, ... Company,s Board of Directors: Philip R. Lochner, Jr., Sheldon M. ... Gentiva has re-established an independent majority on its Board and ...
... PHILADELPHIA, Sept. 3 ERT (Nasdaq: ERES ... thorough QT clinical Trial (TET). ERT provides full TET ... provision of ECG equipment to ECG analysis, data processing, management, ... Cardiac safety concerns continue to be the primary ...
... - NUCRYST Pharmaceuticals, a developer and manufacturer of ... Wound Management division of Smith Nephew ... Flex3 and Acticoat(TM) Flex7. The Flex range is ... dressings with NUCRYST,s proprietary SILCRYST(TM) nanocrystalline silver coatings. ...
... Online ... named to the prestigious 2009 Inc. magazine 500/5000 list of the country,s fastest growing ... ... has been named to the prestigious 2009 Inc. magazine 500/5000 list of the country,s ...
Cached Medicine News:Health News:NIBIB scientists increase imaging efficiency in cell structure studies 2Health News:People with type 2 diabetes not meeting important nutritional recommendations 2Health News:People with type 2 diabetes not meeting important nutritional recommendations 3Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 2Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 3Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 4Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 5Health News:Gentiva(R) Health Services Announces Appointment of Three Independent Directors 6Health News:ERT Achieves Cardiac Safety Milestone after Completing 150th TET Trial 2Health News:ERT Achieves Cardiac Safety Milestone after Completing 150th TET Trial 3Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 2Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 3Health News:European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew 4Health News:My1Stop.com Named 2009 Inc. 500/5000 Honoree 2
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: